Characteristics | N | All | CSPG4 classes | p-value* | |
---|---|---|---|---|---|
low | high | ||||
Patient's age, median | |||||
Years (range) | 528 | 61 (2–92) | 61 (10–92) | 57 (2–90) | 0.032 |
Gender | |||||
Female | 299 | 299 (49%) | 151 (47%) | 148 (52%) | 0.316 |
Male | 306 | 306 (51%) | 168 (53%) | 138 (48%) | |
Tumor site | |||||
Extremity | 206 | 206 (42%) | 124 (47%) | 82 (36%) | 0.007 |
Head and neck | 9 | 9 (2%) | 7 (3%) | 2 (1%) | |
Internal trunk | 195 | 195 (39%) | 87 (33%) | 108 (47%) | |
Superficial trunk | 84 | 84 (17%) | 46 (17%) | 38 (17%) | |
Tumor depth | |||||
Deep | 144 | 144 (89%) | 73 (88%) | 71 (91%) | 0.706 |
Superficial | 17 | 17 (11%) | 10 (12%) | 7 (9%) | |
Pathological type | |||||
Undifferentiated pleomorphic sarcoma | 288 | 288 (21%) | 163 (24%) | 125 (18%) | 7.52E−21 |
Leiomyosarcoma | 311 | 311 (23%) | 87 (13%) | 224 (33%) | |
Liposarcoma | 476 | 476 (35%) | 259 (38%) | 217 (32%) | |
Myxofibrosarcoma | 100 | 100 (7%) | 78 (12%) | 22 (3%) | |
Other | 177 | 177 (13%) | 86 (13%) | 91 (13%) | |
Pathological tumor size, median cm (range) | 170 | 10.0 (1.2–39.5) | 12.53 (1.6–36) | 11.8 (1.2–39.5) | 0.540 |
Pathological FNCLCC grade | |||||
1–2 | 163 | 163 (49%) | 88 (51%) | 75 (48%) | 0.693 |
3 | 166 | 166 (51%) | 85 (49%) | 81 (52%) | |
Genetic profile | |||||
Simple | 508 | 508 (38%) | 269 (40%) | 239 (35%) | 0.095 |
Complex | 844 | 844 (62%) | 406 (60%) | 438 (65%) | |
CINSARC risk | |||||
Low-risk | 724 | 724 (53%) | 381 (55%) | 343 (50%) | 0.046 |
High-risk | 654 | 654 (47%) | 308 (45%) | 346 (50%) | |
TCGA SARC, iCluster | |||||
1 | 48 | 48 (27%) | 2 (2%) | 46 (51%) | 6.51E−14 |
2 | 27 | 27 (15%) | 11 (12%) | 16 (18%) | |
3 | 55 | 55 (30%) | 45 (50%) | 10 (11%) | |
4 | 9 | 9 (5%) | 7 (8%) | 2 (2%) | |
5 | 42 | 42 (23%) | 25 (28%) | 17 (19%) | |
Follow-up median, months (min–max) | 610 | 28 (1–222) | 32 (1–203) | 24 (1–222) | 0.624 |
DFS event | 610 | 223 (27%) | 119 (33%) | 104 (43%) | 1.28E−02 |
5-year DFS [95% CI] | 610 | 56% (52–61) | 61% (56–68) | 49% (42–57) | 3.17E−03 |